News
VIE
53.01
0.00%
0.00
*Carrier Global: EU Approval Marks Final Transaction Regulatory Clearance; Closing Expected Jan 2 >CARR
Dow Jones · 12/18/2023 11:45
Carrier to Buy German Manufacturer Viessmann's Climate Solutions Unit
Dow Jones · 04/25/2023 21:44
*Carrier Global: Acquisition Expected to Be Modestly Dilutive in 2024 to Adj EPS, Accretive in 2025 and Increasingly Accretive Thereafter
Dow Jones · 04/25/2023 20:50
*Carrier Global Sees Acquisition Accretive to Adjusted EPS by Year Two >CARR
Dow Jones · 04/25/2023 20:50
*Carrier Global Will Name Max Viessmann, CEO of Viessmann, to Board at Closing
Dow Jones · 04/25/2023 20:48
*Carrier Global to Acquire Viessmann Climate Solutions for EUR12 B in Cash and Stk >CARR
Dow Jones · 04/25/2023 20:47
*Carrier Global Plans to Exit Its Fire & Security and Comml Refrigeration Businesses >CARR
Dow Jones · 04/25/2023 20:47
Carrier Global Shares Slip After WSJ Report of Viessmann Deal
Dow Jones · 04/24/2023 16:57
More
Webull provides a variety of real-time VIE stock news. You can receive the latest news about Viela Bio Inc through multiple platforms. This information may help you make smarter investment decisions.
About VIE
Viela Bio Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for severe inflammation and autoimmune diseases. Its product pipeline includes Inebilizumab, VIB4920 and VIB7734. Inebilizumab is a humanized mAb that binds to and depletes CD19+ B cells including plasmablasts and plasma cells. VIB4920 is a fusion protein designed to bind to CD40 ligand (CD40L) on activated T cells, blocking the interaction with CD40 expressed on B cells and preventing them from differentiating into plasma cells and memory B cells. VIB7734 is a treatment for autoimmune and related inflammatory diseases.